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ABSTRACT 
 
Trigeminal neuralgia, often called tic douloreux, has been described as one of the worst painful human afflictions. It is a 
craniofacial pain disorder that is characterized by episodes of sharp, severe, lancinating, “electric - like” bolts of pain. Pain of 
trigeminal neuralgia has been compared to severe toothache or even labor pain.  The International Association for the Study of 
Pain defines classical idiopathic trigeminal neuralgia (TN) as “a sudden, usually unilateral, severe, brief, stabbing, recurrent pain 
in the distribution of one or more branches of the fifth cranial nerve.” However, there are variations in presentation that are more 
difficult to diagnose trigeminal neuralgia. The purpose of this article is to review the recent developments, new criteria for 
diagnosis, medical and surgical management. The review article has been prepared doing a literature review from the World 
Wide Web and pubmed/medline. 
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Introduction  
 
The trigeminal nerve (the fifth cranial nerve, also 
called the fifth nerve, or simply CNV or CN5) is 
responsible for sensation in the face. The trigeminal 
nerve is the largest of the cranial nerves and it is 
thought to be one of the factors involved in the cause of 
migraine. Its name - “trigeminal” - is derived from the 
fact that each nerve, one on each side of the pons, has 
three major branches: the ophthalmic nerve (V1), the 
maxillary nerve (V2) and the mandibular nerve (V3). 
The ophthalmic and maxillary nerves are purely 
sensory. The mandibular nerve has both sensory and 
motor functions.[1] Pain, thermal, tactile and 
kinaesthetic sensory stimuli are received from facial 
skin, oropharynx, oral mucous membranes, sinuses, 
teeth, palate, dura and masticatory muscles.  
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Motor fibers extend to the muscles of mastication as 
well as the tensor tympani and tensor veli palatini. The 
trigeminal brain stem nuclei are the spinal trigeminal 
nucleus and tract, the main (or principal) sensory  
nucleus, the mesencephalic nucleus, and the motor 
trigeminal nucleus. The branches of trigeminal nerve 
have their cell bodies in the gasserian (or semilunar) 
ganglion (with the exception of jaw propioceptive 
fibers). The gasserian ganglion resides in Meckel’s 
cave in the temporal bone.[2]There are various other 
health conditions that can cause facial pain, such as 
trigeminal neuralgia.[1]International Association For 
the Study of Pain (IASP) defined trigeminal neuralgia 
as “sudden usually unilateral severe brief stabbing 
recurrent pain in the distribution of one or more 
branches of the Vth cranial nerve”. According to the 
International Headache Society (IHS) the trigeminal 
neuralgia may be defined as “painful unilateral 
affliction of the face characterized by brief electric 
shock like pain limited to the distribution of one or 
more divisions of trigeminal nerve”. Pain is commonly 
evoked by trivial stimuli including washing, shaving, 
smoking, talking and brushing the teeth but may also 
occur spontaneously. The pain is abrupt in onset and 
termination and may remit for varying periods.[3] 
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Historical perspectives of TGN  
 
Historical reviews of facial pain have attempted to 
describe this severe pain over the past 2.5 millennia. 
The ancient Greek physicians Hippocrates, Aretaeus, 
and Galen, described kephalalgias, but their accounts 
were vague and did not clearly correspond with what 
we now term trigeminal neuralgia. The first adequate 
description of trigeminal neuralgia was given in 1671 
by German physician, Johannes Laurentius Bausch, 
who suffered from a lightning like pain in the right 
face. He became unable to speak or eat properly and 
apparently succumbed to malnutrition. John Locke, a 
physician and well-known philosopher, provided the 
first full description of TN by a medical practitioner, 
along with an account of its treatment. In 1677, while 
in Paris, Locke was called in to evaluate the wife of the 
English ambassador, the Countess of Northumberland, 
who was suffering from excruciating pain in the face 
and lower jaw. Locke deliberated whether to prescribe 
"opening medicine" (laxative therapy), because of the 
wintry weather at the time. In spite of the cold and the 
inconvenience he would cause his patient, he 
eventually overcame his reluctance and thoroughly 
purged the Countess. Her pain improved several weeks 
later. Nearly a century after that, two prominent 
clinical accounts were reported, one by Nicolas André 
(Fig. 1) and one by John Fothergill (Fig. 2) that further 
characterized this disease’s entity. In 1756, André 
reported two cases of TN, which he termed tic 
douloureux. He conceptualized the disease in terms of 
convulsions, and he believed that true tonic 
convulsions, tetanus, and spasm clinique belonged in a 
single disease spectrum. The term tic douloureux was 
used to imply contortions and grimaces accompanied 
by violent and unbearable pain. André believed that the 
cause was "vicious nervous liquids" that distressed the 
nerve and caused painful shocks. Using this reasoning, 
he followed the proposal of Maréchal (a contemporary 
surgeon) by applying caustic substances to the 
infraorbital nerve at the infraorbital foramen over a 
period of days until the nerve was destroyed. Fothergill 
described trigeminal neuralgia as "a painful affection of 
the face”. He presented 14 cases of a painful affliction 
of the face. His description of TN has been considered 
an accurate and clear account. In Fothergill's 
description he made the following comments: “The 
affection seems to be peculiar to persons advancing in 
years, and to women more than to men....”. The pain 
comes suddenly and is excruciating; it lasts but a short 
time, perhaps a quarter or half a minute, and then goes 
off; it returns at irregular intervals, sometimes in half 
an hour, sometimes there are two or three repetitions in 
a few minutes. Eating will bring it on some persons. 
Talking, or the least motion of the muscles of the face 
affects others; the gentlest touch of a hand or a 
handkerchief will sometimes bring on the pain, whilst a 
strong pressure on the part has no effect. Fothergill 
asserted that TN was not within the spectrum of a 
convulsive disorder. Instead, he postulated that this 
disease might be the manifestation of some type of 
cancer; he found a hard tumor of the breast in two of 
the 14 cases he presented. Given his meticulous 
description of the clinical symptoms, many thereafter 
referred to this condition as "Fothergill's disease." 
                              
   Fig 1: Portrait of Nicolas Andre                                                        Fig 2: Portrait of John Fothergill 
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Fig 3: Patient with typical 
trigeminal neuralgia, vessels 
compress the trigeminal nerve 
root. 
Fig 4: No vascular compression 
upon the trigeminal nerve root 
in patient with no TN 
Fig 5: Trigger zones in facial 
areas,trigger points (circles)have 
greatest sensitivity 
 
 
Fig 6: Important clinical features of trigeminal neuralgia 
In 1779, John Hunter more clearly characterized the 
entity as a form of "nervous disorder" with reference to 
pain of the teeth, gums, or tongue where the disease 
"does not reside." One hundred fifty years later, the 
neurological surgeon Walter Dandy equated 
neurovascular compression of the trigeminal nerve 
with trigeminal neuralgia.[4-6] 
 
Etiologic/predisposing factors 
 
Trigeminal nerve is the largest of all the cranial nerves. 
Trigeminal neuralgia, also called tic douloureux, 
causes extreme, sporadic, sudden burning or shock-like 
facial pain that lasts from few seconds to several 
minutes and can be physically and mentally 
incapacitating. Most cases are still referred to as 
idiopathic, although many are associated with vascular 
compression of the trigeminal nerve. According to the 
National Institute of Neurological Disorders and 
Stroke, heredity may be a cause of trigeminal 
neuralgia.[7] 
Compression of trigeminal nerve root is the most 
common cause of trigeminal neuralgia. The 
compression occurs usually within few millimeters of 
entering in to the pons. The primary demyelinating 
disorders can also lead to this condition. A few rare 
conditions that can cause trigeminal neuralgia are: 
• Infiltration of nerve root (due to carcinomatous 
deposit within nerve root, gasserian ganglion and 
nerve ) 
• Small infarcts or angiomas in the pons or medulla. 
• Infiltration of gasserian ganglion or the nerve by a 
tumour or amyloid. 
Most widely accepted theory is that majority of cases 
of trigeminal neuralgia are caused by atherosclerotic 
blood vessel (usually the superior cerebellar artery) 
pressing on and grooving the root of trigeminal nerve. 
This pressure results in focal demyelinization and 
hyperexcitability of nerve fibers, which will then fire in 
response to light touch, resulting in brief episodes of 
intense pain.[8] 
Jannetta in 1967 first recognized the focal compression 
of trigeminal nerve root as a major etiological factor 
for the trigeminal neuralgia. Now it is considered as an 
important cause of trigeminal neuralgia in 80-90% of 
cases. The part of nerve root that commonly 
compressed is actually within CNS tissue. There are 
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following compressing lesions that can lead to TGN 
are: 
• Vestibular schwannomas. 
• Meningiomas. 
• Epidermoid cyst etc.[8,9] 
 
Primary demyelinating disorders 
 
A well known complication of multiple sclerosis is 
TGN. The plaque of demyelination encompasses the 
root entry zone of trigeminal nerve in the pons. The 
compression of blood vessel may also contribute in the 
compression of root entry of trigeminal nerve in some 
patient with multiple sclerosis suffering from 
trigeminal neuralgia.[10-14] 
 
Nondemyelinating lesions 
 
Nakamura et al, Golby et al have reported some 
patients with trigeminal neuralgia who were suffering 
from angiomas and small infarcts within the brain 
stem.[15,16] 
 
Familial trigeminal neuralgia 
 
In 1979 Knuckey and Gubbay reported several 
individuals in three generations of family were 
suffering from trigeminal / glossopharyngeal 
neuralgia.[17] 
Coffey et al reported a familial occurrence in Charcot-
Marie-Tooth neuropathy. He described the patients 
from two different families with Charcot-Marie-Tooth 
disease and medically intractable trigeminal neuralgia. 
The patients were treated with percutaneous 
retrogasserian glycerol rhizolysis successfully.[18] 
 
Diabetes 
Neuralgia anywhere in the body including the 
trigeminal neuralgia can also cause by diabetes. 
Diabetes causes the damage of tiny arteries that 
provide circulation to the nerves which lead to nerve 
fibers malfunctions and sometimes nerve loss. 
 
Infectious conditions 
The trigeminal neuralgia can also manifest by 
infectious conditions cerebellopontine angle 
cysticercosis, pons abscess and cases of bacterial 
infections like Mycobacterium leprae, Secondary 
syphilis, Leptospirosis, Shigella etc. 
 
Stress 
According to Beth Israel Medical Center Department 
of Pain Medicine and Palliative Care the trigeminal 
neuralgia can be caused by stress also. Stress leads to 
inflammation of blood vessel which can compress or 
irritate the trigeminal nerve. Patient having the 
trigeminal neuralgia with another cause, the severity of 
painful attacks can worsen by stress.[7] 
 
Pre-trigeminal neuralgia 
A typical initial manifestation that, in some patients, 
precedes the classic presentation of TN, was introduced 
by Symonds. He described a dull continuous, aching 
pain in the upper or lower jaw that later developed in to 
classic paroxysmal pain. This prodromal pain is termed 
as “pre-trigeminal neuralgia” by Mitchell. Similar 
prodromal sensations have also been reported in some 
cases of glossopharyngeal neuralgia. Descriptions of 
PTN have included pain that is mild to moderate in 
intensity, dull, aching, burning, throbbing, soreness of 
gums and toothache.[19,20] 
Fromm GH et al reported 18 patients who subsequently 
developed typical trigeminal neuralgia experienced a 
prodromal pain termed “pre-trigeminal neuralgia.” The 
prodromal pain was described as a toothache or 
sinusitis-like pain lasting up to several hours, 
sometimes triggered by jaw movements or by drinking 
hot or cold liquids. Typical trigeminal neuralgia 
develops a few days to 12 years later, and in all cases 
affected the same division of the trigeminal nerve. Six 
additional patients experiencing what appeared to be 
pre-trigeminal neuralgia became pain-free when taking 
carbamazepine or baclofen.[21] 
 
Classification of trigeminal neuralgia 
 
Based on etiology 
The international headache society (IHS) has classified 
trigeminal neuralgia in to two categories according to 
etiology: 
1. Classical trigeminal neuralgia – In classical 
trigeminal neuralgia there is no cause of the 
symptoms can be identified other than vascular 
compression. 
2. Symptomatic trigeminal neuralgia - 
Symptomatic trigeminal neuralgia has the same 
clinical criteria, but another underlying cause is 
responsible for the symptoms.[22] 
Based upon the specific objective and reproducible 
criteria a classification scheme for trigeminal neuralgia 
was proposed by Eller JL. The classification was based 
on information provided in the patient’s history and 
incorporates seven diagnostic criteria, as follows: 
1 and 2- Trigeminal neuralgia Types 1 and 
2(TN1andTN2) refer to idiopathic, spontaneous facial 
pain that is predominantly episodic (as in TN1) or 
constant (as in TN2) as in nature. 
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3- Trigeminal neuropathic pain results from 
unintentional injury to the trigeminal nerve from 
trauma or surgery. 
4- Trigeminal deafferentation pain results from 
intentional injury to the nerve by peripheral nerve 
ablation, gangliolysis or rhizotomy in attempt to treat 
either TN or other related facial pain. 
5- Symptomatic TN results from multiple sclerosis. 
6- Post-herpetic TN follows a cutaneous herpes zoster 
outbreak in the trigeminal distribution. 
7- The category of atypical facial pain is reversed for 
facial pain secondary to somatoform pain disorder and 
requires psychological testing for diagnostic 
confirmation. 
 
Based on symptoms 
From symptomatic point of view the trigeminal 
neuralgia is classified in to following: 
1-Typical Trigeminal Neuralgia (Tic Douloureux) 
This is the most common form of TN, which has 
previously been termed Classical, Idiopathic and 
Essential TN.  Nearly all cases of typical TN are 
caused by blood vessels compressing the trigeminal 
nerve root as it enters the brain stem. This 
neurovascular or microvascular compression at the 
trigeminal nerve root entry zone may be caused by 
arteries of veins, large or small, that may simply 
contact or indent the trigeminal nerve. (Fig 3) In people 
without TN, blood vessels are usually not in contact 
with the trigeminal nerve root entry zone. (Fig 4) 
Pulsation of vessels upon the trigeminal nerve root do 
not visibly damage the nerve. However, irritation from 
repeated pulsations may lead to changes of nerve 
function, and delivery of abnormal signals to the 
trigeminal nerve nucleus. Over time, this is thought to 
cause hyperactivity of the trigeminal nerve nucleus, 
resulting in the generation of TN pain. The superior 
cerebellar artery is the vessel most often responsible 
for neurovascular compression upon the trigeminal 
nerve root, although other arteries or veins may be the 
culprit vessels. 
 
2 - Atypical trigeminal neuralgia 
Atypical TN is characterized by a unilateral, prominent 
constant and severe aching, boring or burning pain 
superimposed upon otherwise typical TN symptoms. 
This should be differentiated from cases of typical 
TN that develop a minor aching or burning pain within 
the affected distribution of the trigeminal nerve. As in 
typical TN vascular compression, is thought to be the 
cause of many cases of atypical TN. Some authors also 
believe that atypical TN is due to vascular compression 
upon a specific part of the trigeminal nerve (the portio 
minor); while others theorize that atypical TN 
represents a more severe form or progression of typical 
TN.[23] The disorder is sometimes broken down into 
type 1 and type 2. TN type 1 (TN1) is characterized by 
attacks of intense, stabbing pain affecting the mouth, 
cheek, nose, and/or other areas on one side of the face. 
TN type 2 (TN2) is characterized by less intense pain, 
but a constant dull aching or burning pain. Both types 
of pain can occur in the same individual, even at the 
same time. In some cases, the pain can be excruciating 
and incapacitating. TN1 develops due to a blood vessel 
pressing against the trigeminal nerve, but sometimes no 
underlying cause can be identified (idiopathic). TN2 
can be idiopathic, due to compression of the trigeminal 
nerve, or can occur due to a known underlying cause 
such as a tumor or multiple sclerosis. There is no 
consensus or agreed upon classification system for TN. 
TN1 is also known as classical trigeminal neuralgia. 
TN2 was once known as atypical or symptomatic 
TN.[24] 
 
Clinical presentaion 
• Recurring episodes of intense, short-lived spasms 
of pain of the lower portion of the face and the 
jaw.  
• In most cases, pain is limited to one side of the 
face (unilateral).  
• The pain has been compared to a series of 
"electrical shocks" followed by a steady dull ache.  
• The pain often starts and stops rapidly.  
• Intense pain usually lessens rapidly (usually within 
several seconds), but the following dull aching 
pain may persist for as much as one to two 
minutes. For many individuals, pain is completely 
gone in between episodes. However, for some 
individuals, even some individuals with TN1, 
some degree of pain may persist. 
• Some patients are sensitive in certain areas of face 
called trigger zone, which when touched cause an 
attack. These zones are usually near the nose, lips, 
eyes, ears or inside the mouth. (Fig. 5) 
• Pain may be triggered by mild tactile stimuli 
including brushing one’s teeth, washing one’s 
face, shaving, drinking hot or cold drinks, 
chewing, talking, blowing one’s nose, a cool 
breeze, or a light touch to the face.  
• Some episodes may occur without an apparent 
trigger (spontaneously). Consequently, episodes 
can occur repeatedly throughout the day.  
• Episodes rarely occur during sleep. 
• Attacks typically stop for a period of time and then 
return. 
• Over time, the pain tends to grow worse with 
fewer pain-free periods.  
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Major clinical features are summarized in 
Fig.6[24-27] 
 
Diagnosis 
The diagnostic criteria of the International Headache 
Society (IHS) (1988) are as follows: 
1- Paroxysmal attacks of facial pain which last a few 
seconds to less than two minutes. 
2- Pain has at least 4 of the following characteristics: 
• Distribution along one or more divisions of 
the trigeminal nerve. 
• Sudden, intense, sharp, superficial, stabbing or 
burning in quality. 
• Pain intensity is severe.  
• Precipitation from trigger areas, or by certain 
activities such as eating, talking, washing the 
teeth or cleaning the face. 
• Between paroxysms the patient is entirely 
asymptomatic. 
3- Attacks are stereotyped in the individual patient. 
4- No neurological deficit and exclusion of other 
causes.[28] 
The IHS describes TN as unilateral disorder 
characterized by brief electric shock like pain, abrupt in 
onset and termination limited to the distribution of one 
or more division of the trigeminal nerve in the second 
edition. In the second edition the diagnostic criteria for 
classical trigeminal neuralgia are as follows: 
A- Paroxysmal attacks of pain lasting from fraction of 
a second to two minutes, affecting one or more division 
of trigeminal nerve and fulfilling criteria B&C. 
B. Pain has at least one of the following characteristics: 
1- Intense, sharp, superficial or stabbing. 
1- Precipitated from trigger area or by trigger factor. 
C- Attacks are stereotype in the individual patients. 
D- There is no clinically evident neurological defect. 
E- Not attributed to another disorder. 
The IHS description states that between paroxysms the 
patient is usually asymptomatic, but a dull background 
pain may present in some longstanding cases and that 
many, possibly most, patient with this condition have 
compression of the trigeminal root by tortuous or 
aberrant vessels.[29]  
The trigeminal neuralgia association, UK has given the 
following clues that point to a correct diagnosis of 
trigeminal neuralgia: 
1- The degree of pain exceeds the evidence. 
2- Painkillers do not kill the pain. 
3- The pain cannot be pinned down to one specific 
tooth.[30] 
The diagnosis of TN is purely clinical. Haematological 
investigations at regular intervals are important in 
patient on drug therapy. Radiologic investigations are 
important. Secondary TN (e.g. multiple sclerosis, cysts, 
vascular pathologies etc.) can be rule out with help of 
MRI. Sensory testing is not done routinely, but 
quantitative sensory testing (QST) and evoked 
potentials may play an important role in differentiating 
between symptomatic and idiopathic TN.[27]Nurmikko 
and Edridge have proposed their own diagnostic 
criteria for the trigeminal neuralgia (Table:1) 
 
Management of pain  
Administration of anticonvulsant drug was first 
treatment of choice initially, but nowadays varieties of 
effective treatments are available in both forms 
pharmacological as well as surgery. Drugs used as 
pharmacological treatment for trigeminal neuralgia is 
summarized in Table 2.[33-36] 
   
Surgical management 
When trigeminal neuralgia cases become refractory 
then they are referred to a neurosurgeon with special 
interest and experience with trigeminal neuralgia. 
There are following surgical options for the treatment 
of trigeminal neuralgia: 
1. Microvascular decompression 
Target area in microvascular decompression lies at the 
nerve-pons junction. The posterior fossa approached 
through a suboccipital craniotomy. After aspiration of 
cerebrospinal fluid, the operator advances toward the 
nerve by gently retracting the superolateral margin of 
the cerebellum. The most common finding is a segment 
of the superior cerebellar artery compressing the nerve 
at the root entry zone. Anterior inferior cerebellar 
artery or the superior petrosal veins are the less 
frequent cause of the compression. After the arachnoid 
is dissected and the vessel freed, the operator places a 
piece of shredded Teflon left between the vessel and 
the nerve to separate them.[37] 
2. Glycerol gangliolysis 
The procedure can be done under local anesthesia in 
fully awake patients although mild sedation is usually 
used. The needle is inserted into the trigeminal cistern 
through the foramen ovale using similar trajectors as in 
radio-frequency lesioning and balloon compression. 
Needle positioning must be precise to ensure the tip 
lies in ganglion and not the subarachnoid space beneath 
the temporal lobe. Free CSF flow is the norm, except in 
previously treated cases. Fluoroscopic control is 
mandatory but use of radio opaque contrast to visualise 
the cistern varies from centre –to- centre. Once needle 
is optimally placed, the patient is brought in to a sitting 
position and a small test of sterile anhydrous glycerol 
injected. This is followed by small dose increments up 
to a total of 0.1-0.4 ml depending upon the divisions 
involved. Patient is usually able to perceive the effect 
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of injection as tingling or burning sensation in the 
affected divisions. Patient remains in the sitting 
position for 2 hour after injections.   
3. Radiofrequency gangiolysis 
This procedure is carried out under fluoroscopic 
control in intermittently anaesthetized patient. A 
radiofrequency needle is inserted through the foramen 
ovale into Meckel’s cave using bony landmarks. The 
relationship of trigeminal rootlets to the foramen ovale 
is such that by stepwise advancement of the needle the 
third, second and first divisions will be in succession 
stimulated, the closer to the clival line the needle tip is. 
As soon as the needle has entered Meckel’s cave, 
aspiration will usually yield CSF. Once the needle has 
travelled the pre-planned distance, the patient is 
allowed to awake, the stylet replaced by the electrode 
and stimulation of the nerve root carried out.   The 
paraesthesia elicited must confirm to the location of the 
neuralgia, otherwise the needle must be repositioned. 
Once appropriate siting has taken place, the patient is 
anaesthetized again for thermal lesioning. This is 
performed in cycles of 45 to 90 s at temperatures of 60-
900. After each lesioning the patient is awakened and 
manual sensory testing of the face carried out. 
Additional thermal lesions are performed until clear 
hypalgesia has ensued.[31] 
 
Balloon compression 
This procedure is performed under general anesthesia. 
Using fluoroscopic control, a guide needle is inserted 
in to foramen ovale, but not beyond it. Through the 
needle, the fogarty catheter is advanced until its tip lies 
in Meckel’s cave and balloon is slowly inflated with 
0.5 – 1.0 ml of contrast dye until it occupies the cave, 
ensuring adequate compression. Total compression 
times vary from 1-6 min. This produces only a mild 
sensory loss with immediate pain relief in practically 
all patients. There is complete recovery in a matter of 
weeks. The patient usually only requires an overnight 
stay.[31] 
 
Stereotactic radiosurgery 
Several reports have documented the efficacy of 
Gamma Knife® stereotactic radiosurgery for TN. 
Because radiosurgery is the least invasive procedure 
for TN, it is a good treatment option for patients with 
co-morbidities, high-risk medical illness, or pain 
refractory to prior surgical procedures. Radiosurgery is 
a good alternative for most patients with medically 
refractory trigeminal neuralgia, especially those who 
do not want to accept the greater risk of an MVD for a 
greater chance of pain relief[32]. 
Gamma Knife treatment is a simple, relatively painless 
and quite straight- forward process that consists of four 
steps: 
1. Attaching the head frame; 
2. Imaging with MRI or CT scan (for patients with 
pacemakers) 
3. Treatment planning 
4. Treatment 
The head frame 
Placement of the frame on the head of the patient is a 
very important part of the procedure. This frame allows 
the doctor to pinpoint the target area with extremely 
high accuracy. For trigeminal neuralgia patients, the 
target is usually in the vicinity of the root entry zone of 
the fifth cranial nerve. 
Imaging 
During this part of the procedure, most patients are 
awake and alert; however, patients who experience 
anxiety about the MRI or CT scan can be given further 
sedation so that the imaging can be carried out. 
Treatment planning 
During treatment planning, data from the images is 
transferred to a special, highly sophisticated computer. 
Unlike gamma knife treatment for brain tumors in 
which the tumor is outlined, trigeminal neuralgia 
patients will have the nerve outlined in multiple 
imaging sequences. Neurosurgeon and the rest of the 
team will go through a quality assurance process and 
everyone will review and confirm the plan before 
embarking on the actual treatment. 
 
Treatment 
 
Patient will then be taken to the actual Gamma Knife 
Suite where patient will be allowed to lie down in a 
comfortable position. The head frame is now attached 
to the automatic position system (APS). This is a very 
sophisticated computerized robotic system with high 
accuracy. At this point, patient may move his arms and 
legs, but head will actually be fixed. All of this will be 
explained by the nurses and doctors once inside the 
unit.[38,39] 
 
Cyber knife in trigeminal neuralgia 
Because of the intrinsic limitations of current 
stereotactic radiosurgical devices, image-guided 
robotic radiosurgery was developed, and these 
principles are embodied in the CyberKnife® System. 
For patients who had undergone balloon nerve 
compression, glycerol rhizotomy, or percutaneous 
thermorhizotomy, one complication is facial 
paresthesia and/or numbness of varying magnitude. 
This adverse effect may result from injury of the 
trigeminal nerve, causing impairment of sensory nerve 
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transmission. In a recent Stanford CyberKnife 
radiosurgery study, no patient with prior surgery 
developed facial paresthesia following radiosurgery 
treatment. The reduced rate of facial sensory 
disturbance indicates that the effects of radiosurgery 
are both physiologic and histologic due to lesser 
irritation on nerve tissue than other ablative surgeries. 
Cyber Knife technology allows conformal treatment 
along the nerve and permits highly collimator radiation 
beams near the dorsal root entry zone. 
 
Conclusion 
 
Trigeminal neuralgia has an enormous psychological 
effect that can affect the quality and lifestyle of a 
person. A definitive diagnosis of trigeminal neuralgia 
is one of the greatest problems among clinician and 
patients. Trigeminal neuralgia is a rare condition and 
clinician may only see a few cases in their dental 
practice career. Diagnosis of trigeminal neuralgia is 
made clinically with the help of characteristic signs and 
symptoms. Certain imaging modalities such as MRI 
can be used to rule out the underlying cause of 
trigeminal neuralgia including tumour and multiple 
sclerosis. A clinician must be aware of proper 
diagnosis and management of this type of craniofacial 
pain disorder. 
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Table 1: Diagnostic criteria for the trigeminal neuralgia proposed by Nurmikko and Edridge 
 Typical 
TGN(Liverpool 
criteria) 
Atypical TGN(Liverpool 
criteria) 
TGN(IASP and 
IHS definition) 
Trigeminal 
neuropathy 
(Liverpool criteria) 
Site Unilateral Unilateral Unilateral  Unilateral or bilateral 
Quality of pain Sharp, shooting, 
stabbing, lingering 
aftersensations 
Sharp, shooting, stabbing, 
lingering aftersensations, 
burning, smarting 
Sharp, stabbing, 
burning, superficial 
Dull or sharp, 
smarting, steady pain 
with shooting 
sensations 
superimposed. 
Duration of pain 
 
A few seconds at 
most 
Several seconds Brief Any duration, usually 
hours 
Duration of 
paroxysms 
 
Seconds to minutes Seconds to minutes Seconds to two 
minutes 
Continuous with pain-
free spells. 
Refractory 
period 
 
yes yes yes No 
Continuous pain 
 
No Yes, not severe No Dominant feature 
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Allodynia 
 
Small trigger zones. Small trigger zones Limited trigger 
zones 
Large allodynic areas 
Associated 
features 
Vasodialation, 
swelling seen with 
severe pain 
Vasodilatation, swelling 
seen with severe pain. 
Slight flush Variable 
vasodilatation and 
swelling, may be 
constantly present 
Radiation  None outside 
affected division 
None outside affected 
division 
None outside 
affected division 
May extend outside 
trigeminal territory 
Provoking 
factors 
Touching, speaking, 
eating, drinking, 
cold, not heat, 
movement 
Touching, speaking, eating, 
drinking, cold, occasionally 
heat, movement 
Eating, talking, 
washing face, 
brushing teeth and 
smoking. 
Same as atypical TGN 
Variability of 
pain 
Some Variation Definite variation stereotyped Definite variation 
Sensory loss Not detectable with 
bedside test QST 
may be abnormal 
May be detectable with 
bedside tests QST usually 
abnormal 
None Prominent, easily 
detected with bedside 
tests confirmed by 
QST  
Pain behaviour Aversion to touch 
guarded speech 
Aversion to touch guarded 
speech 
Not  discussed Tolerates touching 
speech not affected 
Course of pain Early remissions 
pre- TGN 
Early remissions 
previously typical TGN 
Spontaneous 
remissions 
No remission; slow 
progression 
 
Table 2: Drugs used as pharmacological treatment for trigeminal neuralgia 
Drugs Mechanism of action Dosage Adverse effect 
Carbamazepine Slow the recovery rate of voltage –
gated sodium channels, modulates 
activated calcium channel activity 
and activates descending inhibitory 
modulation system 
200-1200 mg daily in 2 
divided doses 
Memory problems, 
diplopia, drowsiness,  
fatigue, nausea, 
nystagmus liver 
dysfunction, 
hematosupression 
Baclofen Act by facilitating segmental 
inhibition of the trigeminal complex. 
Initial dose is 5mg TID for 
3 days and dose may be 
increase d up to10 to 20 
mg/day every 3 days and 
maximum tolerated dose is 
50 to 60 mg/day 
Drowsiness, Dizziness, 
weakness, Fatigue and 
nausea 
Oxcarbazepine  Act by blocking voltage-gated 
sodium channel and it modulates 
voltage activated Ca++ currents. 
300 to 1800 mg daily in 
two divided doses 
Dizziness, fatigue, ataxia, 
fatigue, tremors, diplopia, 
diminished concentration. 
Phenytoin Promotes sodium reflux from 
neurons. 
300 to 500 mg/day Nystagmus, ataxia, slurred 
speech, mental confusion 
Lamotrigine It acts as a voltage sensitive sodium Starting dose is 25 mg Ataxia, constipation, 
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channel 
and stabilizes neural membranes. 
twice daily and it can be 
increased 
gradually to a maintenance 
dose of 200-400mg/day in 
two divided doses. 
vomiting and rash 
Levetiracetam mechanism of action is thought to 
involve binding to the high voltage 
N type calcium channels 
as well as the synaptic vesicle 
protein 2A (SV2A). 
effective dose range is 
1000 - 4000 
mg/day 
 
 sleepiness, fatigue, 
weakness, headache, pain, 
double vision, dizziness, 
coordination difficulties, 
runny nose or cough, 
increased infections, 
memory difficulties, 
anxiety, and behavioral 
problems 
Gabapentin Mechanism of action is not known 
but possibly includes blockage of 
voltage – gated calcium channels by 
binding to α2/∆ subunit 
1200 to 3600 mg daily in 
3 or 4 divided doses 
dizziness, 
coordination problems,  
nausea, vomiting 
Pregabalin drug binds to the a2d subunit of the 
voltage gated calcium channels 
causing decreased presynaptic 
calcium entry leading to decreased 
synpatic 
release of glutamate. 
150-600 mg/day Ataxia 
Topiramate Acts by sodium channel blockade, 
enhancing GABAA activity by 
binding to a non-benzodiazepine site 
on GABAA receptors, and 
selectively blocking AMPA/kainite 
glutamate receptors. 
50 to 100 mg a day Dizziness, sedation, 
cognitive impairment, 
fatigue, nausea, blurred 
vision and 
weight loss. 
 
 
 
 
